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Objectives: To identify the impact of lower extremity
revascularization or amputation on 30-day mortality in
patients with preoperative do not resuscitate orders
documented.
Methods: Patients were identified from the 2005-
2008 ACS NSQIP datafile using CPT codes. Group-wise
comparisons based on DNR status were performed using
t-tests and 2. Associations between preoperative DNR
status, operative management (categorically evaluated as
revascularization versus amputation), and mortality were
evaluated using logistic regression.
Results: 15,541 operations were identified, of which
9417 were revascularizations and 6,124 were major ampu-
tations. 526 patients were DNR (1.1% of revasculariza-
tions; 6.8% of amputations. DNR patients were older and
had a greater prevalence of preoperative comorbid condi-
tions and abnormal laboratory data. Perioperative mortality
was 22.2% for DNR versus 5% for non-DNR patients
[univariate OR (95% CI) for DNR status: 5.4 (4.4-6.6);
P0.0001]. Multivariable modeling adjusting for preoper-
ative differences in demographic, comorbidity, and labora-
tory data revealed an interaction between DNR status and
procedural management (P0.0013). DNR status was as-
sociated with increased mortality risk following both revas-
cularization [Estimated(OR)(95% CI):4.9 (2.9-8.3)] and
amputation [Estimated (OR)(95% CI):1.9 (1.4-2.5)].
Conclusions: DNR patients are at increased risk for
perioperative mortality following both lower extremity am-
putation and revascularization, and this association be-
tween DNR status and mortality persists after adjusting for
differences in other risk factors. The differential effect on
mortality risk based on procedural management implies
greater risk for DNR patients undergoing revasculariza-
tion, but may reflect the influence of DNR status on
procedure selection given greater prevalence of DNR status
among these patients. DNR status should be considered
during preoperative risk assessment and may inform preop-
erative counseling and decision making.
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Objectives: To evaluate the safety and efficacy of trans-
plantation of purified peripheral blood CD34 cells in
treatment of no-option critical limb ischemia (NOCLI).
Methods: From May 2009 to Nov. 2010, 15 NOCLI
cases were included, 11 with thromboangitis, 2 atheroscle-
rosis obliterans, and 2 vasculitis, mean age 4415years.
G-CSF was subcutaneously injected for 5 days before
apheresis. CD34 cells were isolated with CliniMACS
system, and then intramuscularly injected into calf and foot.
Results: Technical success was achieved in all cases.
Major amputation was performed in 2 cases postopera-
tively, and the salvage rate was 87%. The mean number of
transplanted cells was (7.844.17) 105/kg. The fol-
low-up was accomplished in all cases, ranging from 1-19
months (mean 85months). One month after transplanta-
tion, the rest pain was obviously relieved in 11 cases, and
theWong-Baker FACES pain rating scale score significantly
decreased from 72 to 11, P0.0000. At 6 months, the
pain-free walking distance on treadmill measured in 8 eli-
gible cases was significantly improved from 3.03.0 min to
17.910.6 min (P0.001); the ankle-brachial index in-
creased from 0.450.22 to 0.690.13 ( P0.007); trans-
cutaneous partial oxygen pressure rose from 2912mmHg
to 579mmHg (P0.0002). Of 9 cases with the foot
ulcer, it was healed in 6 patients at 43months and appar-
ently shrank in 3. No serious complications were observed
either perioperatively or during the follow-up.
Conclusions: Transplantation of purified peripheral
blood CD34 cells appeared to be safe and effective in
treatment of NOCLI, and mid-to-long-term results is
pending further investigation.
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Objectives: Treatment options for aorto-ilac occlusive
disease (AIOD) include open and endovascular treatment.
We performed a meta-analysis of studies reporting the
treatment outcomes for AIOD.
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